WELIREG
Total Payments
$123.6M
Transactions
3,118
Doctors
597
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $45.2M | 1,128 | 423 |
| 2023 | $36.3M | 640 | 112 |
| 2022 | $22.0M | 756 | 56 |
| 2021 | $20.1M | 594 | 61 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $122.8M | 1,939 | 99.3% |
| Consulting Fee | $500,682 | 285 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $273,849 | 74 | 0.2% |
| Travel and Lodging | $59,241 | 185 | 0.0% |
| Food and Beverage | $21,189 | 440 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $8,500 | 2 | 0.0% |
| Education | $3,442 | 193 | 0.0% |
Payments by Type
Research
$122.8M
1,939 transactions
General
$866,902
1,179 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma ccRCC | Merck Sharp & Dohme LLC | $19.0M | 0 |
| An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma | Merck Sharp & Dohme LLC | $11.8M | 0 |
| An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | Merck Sharp & Dohme LLC | $10.4M | 0 |
| A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 | Merck Sharp & Dohme LLC | $7.9M | 0 |
| A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy MK-6482-022 | Merck Sharp & Dohme LLC | $7.8M | 0 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, von Hippel-Lindau VHL Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor wt GIST, or Advanced Solid Tumors With HIF-2a related Genetic Alterations | Merck Sharp & Dohme LLC | $6.8M | 0 |
| An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | Merck Sharp & Dohme LLC | $6.2M | 0 |
| A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma | Merck Sharp & Dohme LLC | $5.9M | 0 |
| A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC | Merck Sharp & Dohme LLC | $5.5M | 0 |
| A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | Merck Sharp & Dohme LLC | $5.4M | 0 |
| Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | Merck Sharp & Dohme LLC | $4.7M | 0 |
| An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | Merck Sharp & Dohme Corporation | $4.4M | 0 |
| A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | Merck Sharp & Dohme LLC | $4.4M | 0 |
| An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $3.9M | 0 |
| An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | Merck Sharp & Dohme LLC | $3.4M | 0 |
| Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $3.0M | 0 |
| An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | Merck Sharp & Dohme Corporation | $1.8M | 0 |
| A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $1.7M | 0 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants with Advanced Pheochromocytoma,Paraganglioma PPGL, Pancreatic Neuroendocrine Tumor pNET, or von Hippel-Lindau VHL Disease-Associated Tumors | Merck Sharp & Dohme LLC | $1.5M | 0 |
| An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma ccRCC | Merck Sharp & Dohme Corporation | $1.1M | 0 |
Top Doctors Receiving Payments for WELIREG — Page 24
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , A.R.N.P | Family | Houston, TX | $14.62 | 1 |
| , M.D | Hematology & Oncology | Mountain Lakes, NJ | $14.22 | 1 |
| , M.D | Hematology & Oncology | Mountain Lakes, NJ | $14.22 | 1 |
| , M.D | Hematology | Mountain Lakes, NJ | $14.22 | 1 |
| , M.D., M.P.H | Neurology | Staten Island, NY | $13.85 | 1 |
| , M.D | Neurology | Annandale, NJ | $13.77 | 1 |
| , MD | Hematology | Mobile, AL | $13.21 | 1 |
| , PA-C | Physician Assistant | Portland, OR | $13.21 | 1 |
| , CRNP | Women's Health | Mobile, AL | $13.21 | 1 |
| , CRNP | Nurse Practitioner | Mobile, AL | $13.21 | 1 |
| , PA | Physician Assistant | Amherst, NY | $12.82 | 1 |
| , NP-C | Family | Crestview Hills, KY | $12.50 | 1 |
| , M.D | Urology | Crestview Hills, KY | $12.50 | 1 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $10.87 | 1 |
| , M.D | Hematology | Inverness, FL | $10.85 | 1 |
| , M.D | Specialist | Rockingham, VA | $10.85 | 1 |
| , M.D | Hematology & Oncology | Madison, WI | $10.85 | 1 |
| , MD | Hematology & Oncology | Binghamton, NY | $10.85 | 1 |
| , MD | Hematology & Oncology | Las Vegas, NV | $10.85 | 1 |
| , M.D | Medical Oncology | Athens, GA | $10.85 | 1 |
| , MD | Neurology | Tampa, FL | $10.85 | 1 |
| , M.D | Hematology | Inverness, FL | $10.85 | 1 |
| , M.D | Urology | Worthington, OH | $9.11 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme LLC $103.7M
- Merck Sharp & Dohme Corporation $19.9M
Product Information
- Type Drug
- Total Payments $123.6M
- Total Doctors 597
- Transactions 3,118
About WELIREG
WELIREG is a drug associated with $123.6M in payments to 597 healthcare providers, recorded across 3,118 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2021 to 2024. In 2024, $45.2M was paid across 1,128 transactions to 423 doctors.
The most common payment nature for WELIREG is "Unspecified" ($122.8M, 99.3% of total).
WELIREG is associated with 20 research studies, including "An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma ccRCC" ($19.0M).